David Sarid

1.9k total citations
46 papers, 599 citations indexed

About

David Sarid is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, David Sarid has authored 46 papers receiving a total of 599 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 12 papers in Molecular Biology. Recurrent topics in David Sarid's work include Prostate Cancer Treatment and Research (14 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Renal cell carcinoma treatment (9 papers). David Sarid is often cited by papers focused on Prostate Cancer Treatment and Research (14 papers), Radiopharmaceutical Chemistry and Applications (9 papers) and Renal cell carcinoma treatment (9 papers). David Sarid collaborates with scholars based in Israel, United States and South Korea. David Sarid's co-authors include Noa Ben-Baruch, Adva Yeheskel, Vincent A. Miller, Ido Wolf, Lior Soussan‐Gutman, Myles Brown, Keren Merenbakh-Lamin, Rinath Jeselsohn, Shulamith Rizel and Addie Dvir and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

David Sarid

43 papers receiving 590 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Sarid Israel 12 295 253 205 165 159 46 599
Daniel Brattström Sweden 17 451 1.5× 401 1.6× 365 1.8× 237 1.4× 91 0.6× 43 874
Eduardo Martínez de Dueñas Spain 14 368 1.2× 287 1.1× 257 1.3× 228 1.4× 160 1.0× 49 695
Karen G. Spink United Kingdom 10 278 0.9× 177 0.7× 392 1.9× 169 1.0× 54 0.3× 13 722
Ning Liao China 13 191 0.6× 110 0.4× 197 1.0× 205 1.2× 60 0.4× 48 449
Boriana Zaharieva Bulgaria 9 231 0.8× 75 0.3× 301 1.5× 165 1.0× 104 0.7× 21 575
Yeung Ho United States 12 123 0.4× 248 1.0× 253 1.2× 176 1.1× 70 0.4× 13 537
Jussi P. Elo Finland 8 193 0.7× 263 1.0× 391 1.9× 118 0.7× 164 1.0× 10 719
Tianfeng Wang China 12 331 1.1× 105 0.4× 325 1.6× 222 1.3× 214 1.3× 45 650
Silvia Paola Corona Italy 13 391 1.3× 357 1.4× 230 1.1× 152 0.9× 46 0.3× 43 689
G. Pover United Kingdom 10 434 1.5× 236 0.9× 367 1.8× 129 0.8× 72 0.5× 17 704

Countries citing papers authored by David Sarid

Since Specialization
Citations

This map shows the geographic impact of David Sarid's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Sarid with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Sarid more than expected).

Fields of papers citing papers by David Sarid

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Sarid. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Sarid. The network helps show where David Sarid may publish in the future.

Co-authorship network of co-authors of David Sarid

This figure shows the co-authorship network connecting the top 25 collaborators of David Sarid. A scholar is included among the top collaborators of David Sarid based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Sarid. David Sarid is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Calvo, Emiliano, Bernard Doger, Joan Carles, et al.. (2025). A first-in-human study of JNJ-70218902, a bispecific T-cell-redirecting antibody against TMEFF2 in metastatic castration-resistant prostate cancer. The Oncologist. 30(1). 2 indexed citations
2.
Giannatempo, Patrizia, Jean‐Pascal Machiels, Naoto Sassa, et al.. (2024). Impact of Histology on Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Advanced or Metastatic Urothelial Carcinoma in the Phase 3 KEYNOTE-045 and KEYNOTE-361 Trials. Clinical Genitourinary Cancer. 23(2). 102273–102273.
3.
Cohen, Dan, Charles Levine, David Sarid, et al.. (2023). Staging Prostate Cancer with68Ga-PSMA-11 PET/CT in the Elderly: Is Preimaging Biopsy Imperative?. Journal of Nuclear Medicine. 64(7). 1030–1035. 1 indexed citations
4.
Keizman, Daniel, Moshe Frenkel, Avivit Peer, et al.. (2023). Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Long-Term Results of a Prospective Phase II Study. Nutrients. 15(16). 3533–3533. 6 indexed citations
5.
Keizman, Daniel, Moshe Frenkel, Avivit Peer, et al.. (2023). P-MCP treatment in non-metastatic biochemically relapsed prostate cancer (BRPC-M0): Final long-term results of a prospective phase II study.. Journal of Clinical Oncology. 41(6_suppl). 162–162. 1 indexed citations
6.
Rouvinov, Keren, Avivit Peer, Michal Sarfaty, et al.. (2023). Erdafitinib treatment in metastatic urothelial carcinoma: a real-world analysis. Frontiers in Oncology. 13. 1151701–1151701. 3 indexed citations
7.
8.
Kuten, Jonathan, Jeffrey Campbell, Yuval Bar‐Yosef, et al.. (2022). 68Ga-prostate-specific membrane antigen positron emission tomography/computed tomography for patients with favorable intermediate-risk prostate cancer. Canadian Urological Association Journal. 16(7). E381–E385. 11 indexed citations
9.
Kuten, Jonathan, Charles Levine, David Sarid, et al.. (2021). Staging 68 Ga-PSMA PET/CT in 963 consecutive patients with newly diagnosed prostate cancer: incidence and characterization of skeletal involvement. European Journal of Nuclear Medicine and Molecular Imaging. 49(6). 2077–2085. 13 indexed citations
10.
Kuten, Jonathan, Gilad Gitstein, Daniel Keizman, et al.. (2021). Preoperative 68Ga-PSMA PET/CT defines a subgroup of high-risk prostate cancer patients with favorable outcomes after radical prostatectomy and lymph node dissection. Prostate Cancer and Prostatic Diseases. 24(3). 910–916. 12 indexed citations
11.
Keizman, Daniel, et al.. (2020). The psychological impact of early prostate cancer: A prospective evaluation.. Journal of Clinical Oncology. 38(6_suppl). 210–210. 1 indexed citations
12.
Keizman, Daniel, Hermann Reichegger, Eli Rosenbaum, et al.. (2017). Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastases—analysis of an international multicenter database. Prostate Cancer and Prostatic Diseases. 20(3). 289–293. 37 indexed citations
13.
Neiman, Victoria, Daniel Keizman, David Sarid, et al.. (2016). Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. Annals of Oncology. 27. vi289–vi289.
14.
Keizman, Daniel, Maya Ish‐Shalom, Avishay Sella, et al.. (2016). Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer. 14(5). 420–425. 17 indexed citations
15.
16.
Safra, Tamar, Julia Greenberg, Ilan G. Ron, et al.. (2008). Fulvestrant in heavily pretreated metastatic breast cancer: is it still effective as a very advanced line of treatment?. PubMed. 10(5). 339–43. 3 indexed citations
17.
Sarid, David, et al.. (2006). Neoadjuvant Treatment with Paclitaxel and Epirubicin in Invasive??Breast Cancer. Clinical Drug Investigation. 26(12). 691–701. 13 indexed citations
18.
19.
Sarid, David, et al.. (2004). Cutaneous and subcutaneous metastases of rectal cancer. International Journal of Clinical Oncology. 9(3). 202–5. 40 indexed citations
20.
Sarid, David, et al.. (2002). Spontaneous Regression of Retroperitoneal Metastases From a Primary Pure Anaplastic Seminoma. American Journal of Clinical Oncology. 25(4). 380–382. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Brattström Breakdown of academic impact, for papers by Eduardo Martínez de Dueñas Breakdown of academic impact, for papers by Karen G. Spink Breakdown of academic impact, for papers by Ning Liao Breakdown of academic impact, for papers by Boriana Zaharieva Breakdown of academic impact, for papers by Yeung Ho Breakdown of academic impact, for papers by Jussi P. Elo Breakdown of academic impact, for papers by Tianfeng Wang Breakdown of academic impact, for papers by Silvia Paola Corona Breakdown of academic impact, for papers by G. Pover
Rankless by CCL
2026